| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CMDC.200600271 |
| P698 | PubMed publication ID | 17541990 |
| P2093 | author name string | Stefan A Laufer | |
| Simona Margutti | |||
| P2860 | cites work | Initial sequencing and analysis of the human genome | Q21045365 |
| The Sequence of the Human Genome | Q22065842 | ||
| Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs | Q24305216 | ||
| JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain | Q24308838 | ||
| A protein kinase involved in the regulation of inflammatory cytokine biosynthesis | Q24311139 | ||
| ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation | Q24312012 | ||
| Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis | Q43937884 | ||
| From imidazoles to pyrimidines: new inhibitors of cytokine release | Q44025540 | ||
| Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes | Q44507866 | ||
| Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue | Q44563635 | ||
| Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity | Q44687585 | ||
| Kinase inhibition with BAY 43-9006 in renal cell carcinoma | Q45077916 | ||
| Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases | Q46042185 | ||
| The primary structure of p38 gamma: a new member of p38 group of MAP kinases | Q46763189 | ||
| Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket | Q47982160 | ||
| Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. | Q48009840 | ||
| The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development | Q48219557 | ||
| Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. | Q52198227 | ||
| Kinetics of small molecule inhibitor binding to p38 kinase. | Q52592660 | ||
| JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. | Q54105156 | ||
| Defective T Cell Differentiation in the Absence of Jnk1 | Q58415329 | ||
| Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases | Q61111880 | ||
| 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency | Q71591889 | ||
| Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages | Q73056335 | ||
| Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis | Q73374754 | ||
| Kinetic mechanism for p38 MAP kinase | Q73611887 | ||
| Too many targets, not enough target validation | Q73746187 | ||
| UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines | Q73905120 | ||
| SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors | Q73923170 | ||
| All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways | Q74326128 | ||
| Discovery of a new class of p38 kinase inhibitors | Q74351309 | ||
| Molecular basis for p38 protein kinase inhibitor specificity | Q77648547 | ||
| Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase | Q77906539 | ||
| Substituted isoxazoles as potent inhibitors of p38 MAP kinase | Q80067136 | ||
| Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms | Q24312029 | ||
| Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2 | Q24313872 | ||
| Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases | Q24316962 | ||
| Components of a new human protein kinase signal transduction pathway | Q24319086 | ||
| Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta) | Q24321919 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| The relation between the divergence of sequence and structure in proteins | Q24531519 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site | Q27638349 | ||
| Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity | Q27641774 | ||
| Crystal structure of p38 mitogen-activated protein kinase | Q27733875 | ||
| A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket | Q27735488 | ||
| The structure of mitogen-activated protein kinase p38 at 2.1-A resolution | Q27736668 | ||
| Structural basis of inhibitor selectivity in MAP kinases | Q27765381 | ||
| The protein kinase family: conserved features and deduced phylogeny of the catalytic domains | Q27860528 | ||
| A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells | Q28237789 | ||
| Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles | Q28242608 | ||
| Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development | Q28273613 | ||
| Drug discovery: playing dirty | Q28276831 | ||
| The MAPK signaling cascade | Q28292599 | ||
| Bacterial signalling involving eukaryotic-type protein kinases | Q28293209 | ||
| Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors | Q28297412 | ||
| c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis | Q28343409 | ||
| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Q28364720 | ||
| Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene | Q28507982 | ||
| MAPKs: new JNK expands the group | Q28611010 | ||
| Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines | Q28645934 | ||
| Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta | Q28646538 | ||
| MAP kinases | Q28679111 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 | ||
| The druggable genome | Q29547361 | ||
| Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation | Q29614227 | ||
| ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions | Q29615216 | ||
| A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins | Q29617438 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| The stress-activated protein kinase subfamily of c-Jun kinases | Q29620001 | ||
| Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun | Q29620103 | ||
| The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1. | Q30176864 | ||
| Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution | Q30918621 | ||
| Simple selection criteria for drug-like chemical matter | Q30990966 | ||
| Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? | Q32032942 | ||
| Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead | Q33230876 | ||
| p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials | Q33716182 | ||
| The p38 signal transduction pathway: activation and function | Q33838955 | ||
| The regulation of protein function by multisite phosphorylation--a 25 year update | Q33928103 | ||
| Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death | Q33930576 | ||
| Molecular properties that influence the oral bioavailability of drug candidates | Q34130727 | ||
| Target discovery | Q34267418 | ||
| Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. | Q34306096 | ||
| Discovery of a novel Raf kinase inhibitor | Q34376383 | ||
| The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase | Q34432656 | ||
| Drugs, their targets and the nature and number of drug targets | Q34571023 | ||
| Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies | Q35020561 | ||
| Issues and progress with protein kinase inhibitors for cancer treatment | Q35096214 | ||
| Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. | Q35117306 | ||
| Targeting JNK for therapeutic benefit: from junk to gold? | Q35158010 | ||
| STI571 as a targeted therapy for CML. | Q35193288 | ||
| Medicinal chemistry of target family-directed masterkeys | Q35202868 | ||
| p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases | Q35209995 | ||
| Strategies to overcome resistance to targeted protein kinase inhibitors | Q35968384 | ||
| Treatment of Parkinson's disease : what's on the horizon? | Q36249210 | ||
| The ERK cascade: a prototype of MAPK signaling | Q36260506 | ||
| Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases | Q36264562 | ||
| The discovery of novel chemotypes of p38 kinase inhibitors | Q36264566 | ||
| Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. | Q36264570 | ||
| Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions | Q36264578 | ||
| Small molecular anti-cytokine agents. | Q36311663 | ||
| New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. | Q36384990 | ||
| SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis | Q36494523 | ||
| MAPK signalling: ERK5 versus ERK1/2. | Q36553050 | ||
| Case histories, magic bullets and the state of drug discovery | Q36554410 | ||
| p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis | Q36570509 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. | Q40023699 | ||
| Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase | Q40310115 | ||
| Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent | Q40373664 | ||
| Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate | Q40721991 | ||
| Targeting signal transduction for disease therapy | Q41099705 | ||
| Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase | Q41141283 | ||
| Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. | Q41173912 | ||
| ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK | Q41634356 | ||
| Signal transduction through MAP kinase cascades | Q41750250 | ||
| Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives | Q42439874 | ||
| Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. | Q42537136 | ||
| Pyrroles and other heterocycles as inhibitors of p38 kinase | Q42537156 | ||
| Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution | Q42541263 | ||
| Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site | Q42550034 | ||
| Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro | Q42616486 | ||
| The p150-Spir protein provides a link between c-Jun N-terminal kinase function and actin reorganization | Q42803786 | ||
| Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity | Q43764129 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1116-1140 | |
| P577 | publication date | 2007-08-01 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | Are MAP kinases drug targets? Yes, but difficult ones | |
| P478 | volume | 2 |
| Q38503202 | A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors |
| Q47324721 | A Comprehensive Structural Overview of p38α Mitogen-Activated Protein Kinase in Complex with ATP-Site and Non-ATP-Site Binders |
| Q43122434 | A computational workflow for the design of irreversible inhibitors of protein kinases. |
| Q43258248 | Activity prediction and structural insights of extracellular signal-regulated kinase 2 inhibitors with molecular dynamics simulations. |
| Q54589320 | Assessing protein kinase selectivity with molecular dynamics and mm-pbsa binding free energy calculations. |
| Q51829072 | Frontiers in Medicinal Chemistry 2009--a summary of the meeting at Heidelberg University. |
| Q35250612 | In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. |
| Q52331082 | Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38α MAP Kinase Type-I/II/III Inhibitors. |
| Q34497715 | Roles of prohibitin in growth control and tumor suppression in human cancers |
| Q64997296 | Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-Terminal Kinase 3. |
| Q39058419 | The Pyrazolobenzothiazine Core as a New Chemotype of p38 Alpha Mitogen-Activated Protein Kinase Inhibitors. |
| Q34324047 | The p38alpha mitogen-activated protein kinase limits the CNS proinflammatory cytokine response to systemic lipopolysaccharide, potentially through an IL-10 dependent mechanism |
| Q35762844 | p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening. |
Search more.